Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/SOD1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/SOD1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SOD1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SOD1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SOD1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SOD1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SOD1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SOD1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SOD1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SOD1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SOD1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005188123 | Oral cavity | EOLP | regulation of mitochondrial membrane potential | 18/2218 | 74/18723 | 2.08e-03 | 1.32e-02 | 18 |
GO:200037923 | Oral cavity | EOLP | positive regulation of reactive oxygen species metabolic process | 18/2218 | 76/18723 | 2.85e-03 | 1.69e-02 | 18 |
GO:001407418 | Oral cavity | EOLP | response to purine-containing compound | 29/2218 | 148/18723 | 4.27e-03 | 2.33e-02 | 29 |
GO:190121522 | Oral cavity | EOLP | negative regulation of neuron death | 38/2218 | 208/18723 | 4.28e-03 | 2.34e-02 | 38 |
GO:199074825 | Oral cavity | EOLP | cellular detoxification | 24/2218 | 116/18723 | 4.36e-03 | 2.38e-02 | 24 |
GO:003461424 | Oral cavity | EOLP | cellular response to reactive oxygen species | 30/2218 | 155/18723 | 4.46e-03 | 2.42e-02 | 30 |
GO:000727211 | Oral cavity | EOLP | ensheathment of neurons | 27/2218 | 136/18723 | 4.73e-03 | 2.54e-02 | 27 |
GO:000836611 | Oral cavity | EOLP | axon ensheathment | 27/2218 | 136/18723 | 4.73e-03 | 2.54e-02 | 27 |
GO:003292821 | Oral cavity | EOLP | regulation of superoxide anion generation | 8/2218 | 24/18723 | 4.89e-03 | 2.61e-02 | 8 |
GO:190217523 | Oral cavity | EOLP | regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 9/2218 | 29/18723 | 4.94e-03 | 2.62e-02 | 9 |
GO:0050728 | Oral cavity | EOLP | negative regulation of inflammatory response | 33/2218 | 176/18723 | 4.94e-03 | 2.62e-02 | 33 |
GO:009723725 | Oral cavity | EOLP | cellular response to toxic substance | 25/2218 | 124/18723 | 5.22e-03 | 2.73e-02 | 25 |
GO:005507624 | Oral cavity | EOLP | transition metal ion homeostasis | 27/2218 | 138/18723 | 5.80e-03 | 2.94e-02 | 27 |
GO:00352652 | Oral cavity | EOLP | organ growth | 33/2218 | 178/18723 | 5.89e-03 | 2.97e-02 | 33 |
GO:003293011 | Oral cavity | EOLP | positive regulation of superoxide anion generation | 7/2218 | 20/18723 | 6.20e-03 | 3.09e-02 | 7 |
GO:009875425 | Oral cavity | EOLP | detoxification | 29/2218 | 152/18723 | 6.29e-03 | 3.13e-02 | 29 |
GO:000756521 | Oral cavity | EOLP | female pregnancy | 35/2218 | 193/18723 | 6.67e-03 | 3.26e-02 | 35 |
GO:004274310 | Oral cavity | EOLP | hydrogen peroxide metabolic process | 14/2218 | 58/18723 | 6.71e-03 | 3.28e-02 | 14 |
GO:0036473110 | Oral cavity | EOLP | cell death in response to oxidative stress | 20/2218 | 95/18723 | 7.19e-03 | 3.49e-02 | 20 |
GO:005076411 | Oral cavity | EOLP | regulation of phagocytosis | 20/2218 | 95/18723 | 7.19e-03 | 3.49e-02 | 20 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0501224 | Breast | IDC | Parkinson disease | 107/867 | 266/8465 | 2.57e-39 | 8.36e-37 | 6.26e-37 | 107 |
hsa0502023 | Breast | IDC | Prion disease | 102/867 | 273/8465 | 3.70e-34 | 4.01e-32 | 3.00e-32 | 102 |
hsa0501623 | Breast | IDC | Huntington disease | 103/867 | 306/8465 | 5.14e-30 | 4.17e-28 | 3.12e-28 | 103 |
hsa0501423 | Breast | IDC | Amyotrophic lateral sclerosis | 102/867 | 364/8465 | 1.29e-22 | 5.22e-21 | 3.91e-21 | 102 |
hsa0502223 | Breast | IDC | Pathways of neurodegeneration - multiple diseases | 116/867 | 476/8465 | 3.63e-20 | 1.18e-18 | 8.82e-19 | 116 |
hsa0520824 | Breast | IDC | Chemical carcinogenesis - reactive oxygen species | 71/867 | 223/8465 | 2.55e-19 | 7.53e-18 | 5.63e-18 | 71 |
hsa0501234 | Breast | IDC | Parkinson disease | 107/867 | 266/8465 | 2.57e-39 | 8.36e-37 | 6.26e-37 | 107 |
hsa0502033 | Breast | IDC | Prion disease | 102/867 | 273/8465 | 3.70e-34 | 4.01e-32 | 3.00e-32 | 102 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SOD1 | SNV | Missense_Mutation | | c.315N>G | p.Ile105Met | p.I105M | P00441 | protein_coding | deleterious(0.02) | probably_damaging(0.969) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
SOD1 | SNV | Missense_Mutation | | c.224N>T | p.Pro75Leu | p.P75L | P00441 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
SOD1 | SNV | Missense_Mutation | novel | c.109N>C | p.Lys37Gln | p.K37Q | P00441 | protein_coding | tolerated(0.08) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
SOD1 | SNV | Missense_Mutation | | c.32N>T | p.Gly11Val | p.G11V | P00441 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SOD1 | SNV | Missense_Mutation | | c.446N>C | p.Val149Ala | p.V149A | P00441 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SOD1 | SNV | Missense_Mutation | | c.331N>A | p.His111Asn | p.H111N | P00441 | protein_coding | tolerated(0.7) | benign(0.005) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SOD1 | SNV | Missense_Mutation | rs121912459 | c.289N>A | p.Asp97Asn | p.D97N | P00441 | protein_coding | tolerated(0.29) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SOD1 | SNV | Missense_Mutation | novel | c.239G>T | p.Arg80Met | p.R80M | P00441 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
SOD1 | SNV | Missense_Mutation | novel | c.8C>T | p.Thr3Met | p.T3M | P00441 | protein_coding | tolerated(0.31) | benign(0) | TCGA-AX-A3FX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
SOD1 | SNV | Missense_Mutation | | c.268N>A | p.Ala90Thr | p.A90T | P00441 | protein_coding | tolerated(0.17) | probably_damaging(0.976) | TCGA-BG-A0MG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |